Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Identifying predictors of psychiatric disease in individuals who carry recurrent copy number variations (CNVs).
EF 2016-17
Résumé
Autism spectrum disorder (ASD) and schizophrenia (SCZ) are genetic disorders with high heritability. Individuals with ASD and SCZ have an increased prevalence of common copy number variants (CNVs), i.e. small DNA deletions/duplications, on chromosome regions 1q21.1, 15q13.3, and 16p11.2. However, not all carriers of these CNVs are affected with ASD or SCZ. Our hypothesis is that in the context of other genetic mutations and/or environmental risk factors, these CNVs predispose an individual to neuropsychiatric disease. A collaborative effort, across North America and France, is currently studying patients with our CNVs of interest. As part of this study, CNV carriers are undergoing cognitive testing, neuroimaging and genomic testing. Our role in this study will be to biochemically analyze the samples of these participants using metabolomics. We will perform a non-targeted metabolomic analysis of urine samples from affected and unaffected CNV carriers, as well as controls. All metabolites detected will be quantified and statistically analyzed in order to identify profiles correlating with neuropsychiatric disease. We will explore how these biochemical changes correlate with the results of the aforementioned clinical and genomic characterization of the study participants and try to elucidate the biochemical pathways involved. This study could improve our understanding of the role that these CNVs have in the pathophysiology of ASD and SCZ. Finally, biomarkers predicting which CNV carriers will be affected will potentially allow for clinical trials to explore the impact of earlier intervention in these individuals, for instance, when behavioral abnormalities are present but are still mild.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
367234
Name
MacDonald Kellie A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying predictors of psychiatric disease in individuals who carry recurrent copy number variations (CNVs).
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Behavioural Phenotyping; Biomarkers; Cognitive Phenotyping; Copy Number Variants (Cnvs); Metabolomics
Abstract
Autism spectrum disorder (ASD) and schizophrenia (SCZ) are genetic disorders with high heritability. Individuals with ASD and SCZ have an increased prevalence of common copy number variants (CNVs), i.e. small DNA deletions/duplications, on chromosome regions 1q21.1, 15q13.3, and 16p11.2. However, not all carriers of these CNVs are affected with ASD or SCZ. Our hypothesis is that in the context of other genetic mutations and/or environmental risk factors, these CNVs predispose an individual to neuropsychiatric disease. A collaborative effort, across North America and France, is currently studying patients with our CNVs of interest. As part of this study, CNV carriers are undergoing cognitive testing, neuroimaging and genomic testing. Our role in this study will be to biochemically analyze the samples of these participants using metabolomics. We will perform a non-targeted metabolomic analysis of urine samples from affected and unaffected CNV carriers, as well as controls. All metabolites detected will be quantified and statistically analyzed in order to identify profiles correlating with neuropsychiatric disease. We will explore how these biochemical changes correlate with the results of the aforementioned clinical and genomic characterization of the study participants and try to elucidate the biochemical pathways involved. This study could improve our understanding of the role that these CNVs have in the pathophysiology of ASD and SCZ. Finally, biomarkers predicting which CNV carriers will be affected will potentially allow for clinical trials to explore the impact of earlier intervention in these individuals, for instance, when behavioral abnormalities are present but are still mild.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
MacDonald, Kellie A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~